Mirna Therapeutics Inc., an Austin, Texas-based biopharmaceutical company focused on the development and commercialization of microRNA (miRNA) therapeutics in cancer, has completed a $34.5m Series C financing.
The company intends to use the capital to advance its lead microRNA-based therapeutic product candidate MRX34 through human proof of concept studies.
Led by Paul Lammers, M.D., President and Chief Executive Officer, Matthew Winkler, Ph.D., and Director and founder, Mirna aims to leverage tumor suppressor micro RNAs (miRNAs) to kill cancer cells by regaining control over multiple oncogenic pathways. The company’s miRNA “mimic pipeline” has broad therapeutic utility in solid and hematologic cancers as well as other therapeutic areas, and provides multiple opportunities for partnering and licensing.
In conjunction with the financing, Michael Powell Ph.D., General Partner, Sofinnova Ventures, Ed Mathers, Partner at NEA, and Elaine Jones, Ph.D., Executive Director, Venture Capital-Worldwide Business Development, Pfizer Inc., will join Mirna’s Board of Directors.